Portal de Periódicos da CAPES

Gene therapy with mesenchymal stem cells expressing IFN‐ß ameliorates neuroinflammation in experimental models of multiple sclerosis

2016; Wiley; Volume: 174; Issue: 3 Linguagem: Inglês

10.1111/bph.13674

1476-5381

Carmen Marín-Bañasco, Karim Benabdellah, Carolina Melero‐Jerez, Begoña Oliver‐Martos, María Jesús Pinto-Medel, Isaac Hurtado-Guerrero, Fernando de Castro, Diego Clemente, Óscar Fernández, Francisco Martı́n, Laura Leyva, Margarita Suardíaz,

Neurogenesis and neuroplasticity mechanisms

Recombinant IFN-ß is one of the first-line treatments in multiple sclerosis (MS), despite its lack of efficacy in some patients. In this context, mesenchymal stem cells (MSCs) represent a promising therapeutic alternative due to their immunomodulatory properties and multipotency. Moreover, by taking advantage of their pathotropism, these cells can be genetically modified to be used as carriers for delivering or secreting therapeutic drugs into injured tissues. Here, we report the therapeutic effect of systemic delivery of adipose-derived MSCs (AdMSCs), transduced with the IFN-β gene, into mice with experimental autoimmune encephalomyelitis (EAE).